FindTrial
Sign In

STA-9090

DRUG9 trials

Sponsors

Synta Pharmaceuticals Corp., Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, David M. Jackman, MD, Dana-Farber Cancer Institute

Conditions

Adenocarcinoma of the PancreasBreast CancerColon CancerEsophagogastric CancerHepatocellular CarcinomaMelanomaOcular MelanomaRectal Cancer

Phase 1

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
CompletedNCT00687934
Synta Pharmaceuticals Corp.Solid Tumors
Start: 2007-10-31End: 2011-10-31Updated: 2014-09-18
STA-9090 in Patients With Advanced Hepatocellular Cancer
CompletedNCT01665937
Massachusetts General HospitalHepatocellular Carcinoma
Start: 2010-08-31End: 2014-03-31Updated: 2018-04-25

Phase 2

Clinical and Translational Study of STA-9090
CompletedNCT01111838
Memorial Sloan Kettering Cancer CenterColon Cancer, Rectal Cancer
Start: 2010-04-30End: 2012-07-31Updated: 2015-11-20
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
CompletedNCT01167114
Massachusetts General HospitalEsophagogastric Cancer
Start: 2010-08-31End: 2017-04-30Updated: 2023-11-02
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
CompletedNCT01173523
David M. Jackman, MDSmall Cell Lung Cancer
Start: 2010-07-28End: 2016-11-04Updated: 2019-04-16
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
CompletedNCT01200238
Dana-Farber Cancer InstituteOcular Melanoma
Start: 2010-09-17End: 2016-11-11Updated: 2018-10-18
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
TerminatedNCT01227018
Vanderbilt-Ingram Cancer CenterAdenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Start: 2010-12-31End: 2013-05-31Updated: 2014-07-23
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
CompletedNCT01273896
Memorial Sloan Kettering Cancer CenterBreast Cancer
Start: 2011-01-31End: 2013-09-30Updated: 2015-11-20
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
TerminatedNCT01551693
Dana-Farber Cancer InstituteMelanoma
Start: 2011-09-30End: 2012-09-30Updated: 2017-04-12

Related Papers

A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC).
Journal of Clinical Oncology2014-01-205 citations
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
2013-03-2590 citations